公开(公告)号：US20220315924A1

公开(公告)日：2022-10-06

申请号：US17658957

申请日：2022-04-12

申请人： Medizinische Hochschule Hannover

发明人： Thomas THUM ,  Kumarswamy REGALLA ,  Janika VIERECK

IPC分类号： C12N15/113 ,  A61K48/00 ,  A61P9/00 ,  C12Q1/6883

摘要： The present invention relates to a pharmaceutical composition comprising (i) a compound promoting the expression and/or the activity of one or more long non-coding RNAs (lncRNAs) selected from SEQ ID NOs 12, 8 to 11 and 13; and/or (ii) a compound inhibiting the expression and/or the activity of one or more lncRNAs selected from SEQ ID NOs 1 to 7, 27 and 28. The present invention also relates to a compound (i) promoting the expression and/or the activity of one or more lncRNAs selected from SEQ ID NOs 12, 8 to 11 and 13; and/or (ii) inhibiting the expression and/or the activity of one or more lncRNAs selected from SEQ ID NOs 1 to 7, 27 and 28 for use in treating or preventing cardiac hypertrophy.

公开(公告)号：US20170183652A1

公开(公告)日：2017-06-29

申请号：US15305976

申请日：2015-04-22

申请人： Medizinische Hochschule Hannover

发明人： Thomas THUM ,  Kumarswamy REGALLA ,  Janika VIERECK

IPC分类号： C12N15/113 ,  A61K48/00 ,  C12Q1/68

摘要： The present invention relates to a pharmaceutical composition comprising (i) a compound promoting the expression and/or the activity of one or more long non-coding RNAs (lncRNAs) selected from SEQ ID NOs 12, 8 to 11 and 13; and/or (ii) a compound inhibiting the expression and/or the activity of one or more lncRNAs selected from SEQ ID NOs 1 to 7, 27 and 28. The present invention also relates to a compound (i) promoting the expression and/or the activity of one or more lncRNAs selected from SEQ ID NOs 12, 8 to 11 and 13; and/or (ii) inhibiting the expression and/or the activity of one or more lncRNAs selected from SEQ ID NOs 1 to 7, 27 and 28 for use in treating or preventing cardiac hypertrophy.

公开(公告)号：US20220348920A1

公开(公告)日：2022-11-03

申请号：US17811995

申请日：2022-07-12

申请人： Medizinische Hochschule Hannover

发明人： Thomas THUM ,  Kumarswamy REGALLA ,  Janika VIERECK

IPC分类号： C12N15/113 ,  A61K48/00 ,  A61P9/00 ,  C12Q1/6883

摘要： The present invention relates to a pharmaceutical composition comprising (i) a compound promoting the expression and/or the activity of one or more long non-coding RNAs (lncRNAs) selected from SEQ ID NOs 12, 8 to 11 and 13; and/or (ii) a compound inhibiting the expression and/or the activity of one or more lncRNAs selected from SEQ ID NOs 1 to 7, 27 and 28. The present invention also relates to a compound (i) promoting the expression and/or the activity of one or more lncRNAs selected from SEQ ID NOs 12, 8 to 11 and 13; and/or (ii) inhibiting the expression and/or the activity of one or more lncRNAs selected from SEQ ID NOs 1 to 7, 27 and 28 for use in treating or preventing cardiac hypertrophy.

公开(公告)号：US20190136236A1

公开(公告)日：2019-05-09

申请号：US16098793

申请日：2017-04-26

申请人： MEDIZINISCHE HOCHSCHULE HANNOVER

发明人： Thomas THUM ,  Maria-Teresa PICCOLI ,  Janika VIERECK ,  Shashi Kumar GUPTA

IPC分类号： C12N15/113 ,  C12Q1/6883

摘要： The present invention relates to a compound inhibiting the expression and/or the activity of maternally expressed 3 (Meg3) for use in treating or preventing cardiac remodelling.